Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gideon M Blumenthal

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analysesGideon M Blumenthal, Stella W Karuri, Hui Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2016
Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung CancerSean Khozin, Chana Weinstock, Gideon M Blumenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2018
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell LymphomaNajat Bouchkouj, Yvette L Kasamon, R Angelo de Claro, et al.
JAMA Oncology|September 13, 2019
Global Variation in Opioid Use in Prostate Cancer TrialsJessica K Roydhouse, Daniel L Suzman, Laurel A Menapace, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2019
Challenges with Novel Clinical Trial Designs: Master ProtocolsMichael Cecchini, Eric H Rubin, Gideon M Blumenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2019
FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young AdultsRuo-Jing Li, Runyan Jin, Chao Liu, et al.
Therapeutic Innovation & Regulatory Science|September 1, 2020
Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung CancerPhil Bonomi, Nina Stuccio, C J Delgra, et al.
The Oncologist|May 24, 2017
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing ChemotherapyErin Larkins, Gideon M Blumenthal, Weishi Yuan, et al.
JAMA Oncology|March 2, 2018
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A ReviewJulia A Beaver, Lynn J Howie, Lorraine Pelosof, et al.
JCO Clinical Cancer Informatics|July 23, 2021
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast CancerJeremy Mason, Yutao Gong, Laleh Amiri-Kordestani, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analysesGideon M Blumenthal, Stella W Karuri, Hui Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2016
Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung CancerSean Khozin, Chana Weinstock, Gideon M Blumenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2018
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell LymphomaNajat Bouchkouj, Yvette L Kasamon, R Angelo de Claro, et al.
JAMA Oncology|September 13, 2019
Global Variation in Opioid Use in Prostate Cancer TrialsJessica K Roydhouse, Daniel L Suzman, Laurel A Menapace, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2019
Challenges with Novel Clinical Trial Designs: Master ProtocolsMichael Cecchini, Eric H Rubin, Gideon M Blumenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2019
FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young AdultsRuo-Jing Li, Runyan Jin, Chao Liu, et al.
Therapeutic Innovation & Regulatory Science|September 1, 2020
Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung CancerPhil Bonomi, Nina Stuccio, C J Delgra, et al.
The Oncologist|May 24, 2017
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing ChemotherapyErin Larkins, Gideon M Blumenthal, Weishi Yuan, et al.
JAMA Oncology|March 2, 2018
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A ReviewJulia A Beaver, Lynn J Howie, Lorraine Pelosof, et al.
JCO Clinical Cancer Informatics|July 23, 2021
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast CancerJeremy Mason, Yutao Gong, Laleh Amiri-Kordestani, et al.
Pageof 9